Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams
Background: Extended-spectrum beta-lactamase (ESBL) and carbapenemase (KPC<sup>+</sup>) producing <i>Klebsiella pneumoniae</i> are multidrug-resistant bacteria (MDR) with the highest risk to human health. The significant reduction of new antibiotics development can be overcom...
Guardado en:
Autores principales: | , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a4441cf2c8494ccf9bdf02e9c30745ef |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:a4441cf2c8494ccf9bdf02e9c30745ef |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:a4441cf2c8494ccf9bdf02e9c30745ef2021-11-25T18:41:30ZEffective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams10.3390/pharmaceutics131118891999-4923https://doaj.org/article/a4441cf2c8494ccf9bdf02e9c30745ef2021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1889https://doaj.org/toc/1999-4923Background: Extended-spectrum beta-lactamase (ESBL) and carbapenemase (KPC<sup>+</sup>) producing <i>Klebsiella pneumoniae</i> are multidrug-resistant bacteria (MDR) with the highest risk to human health. The significant reduction of new antibiotics development can be overcome by complementing with alternative therapies, such as antimicrobial photodynamic therapy (aPDI). Through photosensitizer (PS) compounds, aPDI produces local oxidative stress-activated by light (photooxidative stress), nonspecifically killing bacteria. Methodology: Bimetallic Re(I)-based compounds, PSRe-µL1 and PSRe-µL2, were tested in aPDI and compared with a Ru(II)-based PS positive control. The ability of PSRe-µL1 and PSRe-µL2 to inhibit <i>K. pneumoniae</i> was evaluated under a photon flux of 17 µW/cm<sup>2</sup>. In addition, an improved aPDI effect with imipenem on KPC<sup>+</sup> bacteria and a synergistic effect with cefotaxime on ESBL producers of a collection of 118 clinical isolates of <i>K. pneumoniae</i> was determined. Furthermore, trypan blue exclusion assays determined the PS cytotoxicity on mammalian cells. Results: At a minimum dose of 4 µg/mL, both the PSRe-µL1 and PSRe-µL2 significantly inhibited in 3log<sub>10</sub> (>99.9%) the bacterial growth and showed a lethality of 60 and 30 min of light exposure, respectively. Furthermore, they were active on clinical isolates of <i>K. pneumoniae</i> at 3–6 log<sub>10</sub>. Additionally, a remarkably increased effectiveness of aPDI was observed over KPC<sup>+</sup> bacteria when mixed with imipenem, and a synergistic effect from 3 to 6log<sub>10</sub> over ESBL producers of <i>K. pneumoniae</i> clinic isolates when mixed with cefotaxime was determined for both PSs. Furthermore, the compounds show no dark toxicity and low light-dependent toxicity in vitro to mammalian HEp-2 and HEK293 cells. Conclusion: Compounds PSRe-µL1 and PSRe-µL2 produce an effective and synergistic aPDI effect on KPC<sup>+</sup>, ESBL, and clinical isolates of <i>K. pneumoniae</i> and have low cytotoxicity in mammalian cells.Iván A. GonzálezAnnegrett PalavecinoConstanza NúñezPaulina DreyseFelipe Melo-GonzálezSusan M. BuenoChristian Erick PalavecinoMDPI AGarticlephotodynamic therapymulti-drug resistanceantibiotic synergy<i>Klebsiella pneumoniae</i>Pharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1889, p 1889 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
photodynamic therapy multi-drug resistance antibiotic synergy <i>Klebsiella pneumoniae</i> Pharmacy and materia medica RS1-441 |
spellingShingle |
photodynamic therapy multi-drug resistance antibiotic synergy <i>Klebsiella pneumoniae</i> Pharmacy and materia medica RS1-441 Iván A. González Annegrett Palavecino Constanza Núñez Paulina Dreyse Felipe Melo-González Susan M. Bueno Christian Erick Palavecino Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams |
description |
Background: Extended-spectrum beta-lactamase (ESBL) and carbapenemase (KPC<sup>+</sup>) producing <i>Klebsiella pneumoniae</i> are multidrug-resistant bacteria (MDR) with the highest risk to human health. The significant reduction of new antibiotics development can be overcome by complementing with alternative therapies, such as antimicrobial photodynamic therapy (aPDI). Through photosensitizer (PS) compounds, aPDI produces local oxidative stress-activated by light (photooxidative stress), nonspecifically killing bacteria. Methodology: Bimetallic Re(I)-based compounds, PSRe-µL1 and PSRe-µL2, were tested in aPDI and compared with a Ru(II)-based PS positive control. The ability of PSRe-µL1 and PSRe-µL2 to inhibit <i>K. pneumoniae</i> was evaluated under a photon flux of 17 µW/cm<sup>2</sup>. In addition, an improved aPDI effect with imipenem on KPC<sup>+</sup> bacteria and a synergistic effect with cefotaxime on ESBL producers of a collection of 118 clinical isolates of <i>K. pneumoniae</i> was determined. Furthermore, trypan blue exclusion assays determined the PS cytotoxicity on mammalian cells. Results: At a minimum dose of 4 µg/mL, both the PSRe-µL1 and PSRe-µL2 significantly inhibited in 3log<sub>10</sub> (>99.9%) the bacterial growth and showed a lethality of 60 and 30 min of light exposure, respectively. Furthermore, they were active on clinical isolates of <i>K. pneumoniae</i> at 3–6 log<sub>10</sub>. Additionally, a remarkably increased effectiveness of aPDI was observed over KPC<sup>+</sup> bacteria when mixed with imipenem, and a synergistic effect from 3 to 6log<sub>10</sub> over ESBL producers of <i>K. pneumoniae</i> clinic isolates when mixed with cefotaxime was determined for both PSs. Furthermore, the compounds show no dark toxicity and low light-dependent toxicity in vitro to mammalian HEp-2 and HEK293 cells. Conclusion: Compounds PSRe-µL1 and PSRe-µL2 produce an effective and synergistic aPDI effect on KPC<sup>+</sup>, ESBL, and clinical isolates of <i>K. pneumoniae</i> and have low cytotoxicity in mammalian cells. |
format |
article |
author |
Iván A. González Annegrett Palavecino Constanza Núñez Paulina Dreyse Felipe Melo-González Susan M. Bueno Christian Erick Palavecino |
author_facet |
Iván A. González Annegrett Palavecino Constanza Núñez Paulina Dreyse Felipe Melo-González Susan M. Bueno Christian Erick Palavecino |
author_sort |
Iván A. González |
title |
Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams |
title_short |
Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams |
title_full |
Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams |
title_fullStr |
Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams |
title_full_unstemmed |
Effective Treatment against ESBL-Producing <i>Klebsiella pneumoniae</i> through Synergism of the Photodynamic Activity of Re (I) Compounds with Beta-Lactams |
title_sort |
effective treatment against esbl-producing <i>klebsiella pneumoniae</i> through synergism of the photodynamic activity of re (i) compounds with beta-lactams |
publisher |
MDPI AG |
publishDate |
2021 |
url |
https://doaj.org/article/a4441cf2c8494ccf9bdf02e9c30745ef |
work_keys_str_mv |
AT ivanagonzalez effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams AT annegrettpalavecino effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams AT constanzanunez effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams AT paulinadreyse effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams AT felipemelogonzalez effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams AT susanmbueno effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams AT christianerickpalavecino effectivetreatmentagainstesblproducingiklebsiellapneumoniaeithroughsynergismofthephotodynamicactivityofreicompoundswithbetalactams |
_version_ |
1718410791888093184 |